Last reviewed · How we verify

Fluzone High-dose Influenza Vaccine

University Health Network, Toronto · Phase 3 active Biologic

Fluzone High-dose Influenza Vaccine is a Inactivated influenza vaccine Biologic drug developed by University Health Network, Toronto. It is currently in Phase 3 development for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised adults.

Fluzone High-dose stimulates a stronger immune response against influenza by delivering four times the standard antigen dose per strain, enhancing antibody production and cellular immunity in older adults.

Fluzone High-dose stimulates a stronger immune response against influenza by delivering four times the standard antigen dose per strain, enhancing antibody production and cellular immunity in older adults. Used for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised adults.

At a glance

Generic nameFluzone High-dose Influenza Vaccine
SponsorUniversity Health Network, Toronto
Drug classInactivated influenza vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

The vaccine contains inactivated influenza virus antigens at a higher concentration (60 μg per strain vs. 15 μg in standard-dose formulations). This increased antigen load triggers more robust activation of B cells and T cells, leading to higher titers of neutralizing antibodies and improved cell-mediated immunity. This enhanced immunogenicity is particularly beneficial in elderly populations whose immune systems are naturally less responsive to standard vaccines.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluzone High-dose Influenza Vaccine

What is Fluzone High-dose Influenza Vaccine?

Fluzone High-dose Influenza Vaccine is a Inactivated influenza vaccine drug developed by University Health Network, Toronto, indicated for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised adults.

How does Fluzone High-dose Influenza Vaccine work?

Fluzone High-dose stimulates a stronger immune response against influenza by delivering four times the standard antigen dose per strain, enhancing antibody production and cellular immunity in older adults.

What is Fluzone High-dose Influenza Vaccine used for?

Fluzone High-dose Influenza Vaccine is indicated for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised adults.

Who makes Fluzone High-dose Influenza Vaccine?

Fluzone High-dose Influenza Vaccine is developed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).

What drug class is Fluzone High-dose Influenza Vaccine in?

Fluzone High-dose Influenza Vaccine belongs to the Inactivated influenza vaccine class. See all Inactivated influenza vaccine drugs at /class/inactivated-influenza-vaccine.

What development phase is Fluzone High-dose Influenza Vaccine in?

Fluzone High-dose Influenza Vaccine is in Phase 3.

What are the side effects of Fluzone High-dose Influenza Vaccine?

Common side effects of Fluzone High-dose Influenza Vaccine include Injection site soreness, Myalgia, Headache, Fatigue, Fever.

Related